Despite advances in genetic testing and diagnosis, no effective treatments currently exist that can improve long-term neurodevelopmental outcomes in KCNQ2-associated neonatal-onset DEE, highlighting the need to explore the underlying mechanisms of these mutations. This evidence concerns the gene KCNQ2 and developmental and epileptic encephalopathy.